Skip to main content

Table 2 Associations between TNF-α and TNFRSF1B genotypes and overall survival of NSCLC patients

From: TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy

Genotypes No. of patients No. of Deaths MST (months) Crude HR (95% CI) Adjusted HR (95% CI)a Adjusted P a
TNF-α -308 G>A (rs1800629)
   GG 163 112 (68.7) 23.5 1.00 1.00  
   AG 56 39 (69.6) 23.2 1.04 (0.72-1.50) 0.95 (0.65-1.40) 0.802
   AA 6 4 (66.7) 18.1 1.18 (0.44-3.21) 1.10 (0.39-3.11) 0.859
   AG+AA 61 43 (70.5) 23.1 1.05 (0.74-1.50) 0.96 (0.67-1.40) 0.849
   AG+GG 219 151 (68.9) 23.4 1.00 1.00  
   AA 6 4 (66.7) 18.1 1.17(0.43-3.16) 1.11 (0.40-3.13) 0.840
TNF-α -1031T>C (rs1799964)
   TT 137 95 (69.3) 23.4 1.00 1.00  
   CT 77 50 (64.9) 22.1 0.96 (0.68-1.35) 0.89 (0.62-1.28) 0.542
   CC 11 10 (90.9) 23.1 1.28 (0.67-2.46) 1.41 (0.70-2.87) 0.341
   CT+CC 88 60 (68.2) 23.1 1.00 (0.72-1.38) 0.95 (0.68-1.34) 0.785
   CT+TT 214 145 (67.8) 23.4 1.00 1.00  
   CC 11 10 (90.9) 23.1 1.30(0.68-2.47) 1.46 (0.73-2.94) 0.289
TNFRSF1B +676 T>G (rs1061622)
   TT 124 85 (68.5) 23.4 1.00 1.00  
   GT 90 65 (72.2) 21.8 1.10 (0.80-1.52) 1.19 (0.84-1.69) 0.323
   GG 11 5 (45.5) 41.1b 0.36 (0.14-0.88) 0.38 (0.15-0.94) 0.037
   GT+GG 101 70 (69.3) 23.2 0.96 (0.70-1.31) 1.01 (0.72-1.42) 0.937
   GT+TT 214 150 (70.1) 22.7 1.00 1.00  
   GG 11 5 (45.5) 41.1b 0.34 (0.14-0.84) 0.35 (0.14-0.88) 0.026
TNFRSF1B -1709A>T (rs652625)
   AA 207 144 (69.6) 23.2 1.00 1.00  
   AT 15 9 (60.0) 27.8 0.86 (0.44-1.69) 0.85 (0.42-1.71) 0.649
   TT 3 2 (66.7) 15.1 0.94 (0.23-3.82) 1.02 (0.23-4.47) 0.976
   AT+TT 18 11 (61.1) 26.7 0.88 (0.47-1.62) 0.87 (0.46-1.67) 0.685
   AT+AA 222 153 (68.9) 23.4 1.00 1.00  
   TT 3 2 (66.7) 15.1 0.95 (0.24-3.85) 1.05 (0.24-4.58) 0.946
TNFRSF1B +1663A>G(rs1061624)
   AA 67 46 (68.7) 23.4 1.00 1.00  
   AG 89 63 (70.8) 21.1 1.06 (0.73-1.53) 0.98 (0.68-1.43) 0.921
   GG 62 41 (66.1) 28.1 0.84 (0.56-1.26) 0.79 (0.52-1.20) 0.269
   AG+GG 151 104 (68.9) 24.0 1.03(0.73-1.46) 0.96 (0.67-1.37) 0.824
   AG+AA 156 109 (69.9) 22.7 1.00 1.00  
   GG 62 41 (66.1) 28.1 0.84 (0.59-1.20) 0.81 (0.56-1.18) 0.275
  1. MST: median survival time; HR: hazard ratio
  2. aAdjusted for age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose.
  3. bMean survival time was provided when MST could not be calculated.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us